Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study

Cyclophosphamide (CPA) dosing by body surface area (BSA, m(2)) has been questioned as a predictor for individual drug exposure. This study investigated phosphoramide mustard-hemoglobin (PAM-Hb, pmol g(−1) Hb) as a biomarker of CPA exposure in 135 female breast cancer patients receiving CPA during th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gernaat, S. A. M., von Stedingk, H., Hassan, M., Nilsson, H. P., Rodriguez-Wallberg, K. A., Hedayati, E., Rydberg, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851165/
https://www.ncbi.nlm.nih.gov/pubmed/33526812
http://dx.doi.org/10.1038/s41598-021-81662-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851165/
https://www.ncbi.nlm.nih.gov/pubmed/33526812
http://dx.doi.org/10.1038/s41598-021-81662-1

Ejemplares similares